These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections. Hickey DK; Aldwell FE; Beagley KW Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810 [TBL] [Abstract][Full Text] [Related]
28. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856 [TBL] [Abstract][Full Text] [Related]
29. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. Muhamed G; Greenbaum E; Zakay-Rones Z Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048 [TBL] [Abstract][Full Text] [Related]
30. Replication kinetics of duck virus enteritis vaccine virus in ducklings immunized by the mucosal or systemic route using real-time quantitative PCR. Qi X; Yang X; Cheng A; Wang M; Guo Y; Jia R Res Vet Sci; 2009 Feb; 86(1):63-7. PubMed ID: 18565557 [TBL] [Abstract][Full Text] [Related]
31. Bioadhesive delivery systems for mucosal vaccine delivery. Baudner BC; O'Hagan DT J Drug Target; 2010 Dec; 18(10):752-70. PubMed ID: 21039314 [TBL] [Abstract][Full Text] [Related]
32. Mucosal vaccination and therapy with genetically modified lactic acid bacteria. Wells J Annu Rev Food Sci Technol; 2011; 2():423-45. PubMed ID: 22129390 [TBL] [Abstract][Full Text] [Related]
33. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356 [TBL] [Abstract][Full Text] [Related]
34. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? Belyakov IM; Ahlers JD J Immunol; 2009 Dec; 183(11):6883-92. PubMed ID: 19923474 [TBL] [Abstract][Full Text] [Related]
35. New generation of mucosal adjuvants for the induction of protective immunity. Yuki Y; Kiyono H Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340 [TBL] [Abstract][Full Text] [Related]
36. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762 [TBL] [Abstract][Full Text] [Related]
37. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers. Li N; Peng LH; Chen X; Nakagawa S; Gao JQ Vaccine; 2011 Aug; 29(37):6179-90. PubMed ID: 21740946 [TBL] [Abstract][Full Text] [Related]
38. [Comparative study of various routes of vaccination and testing. An instance of a killed bacterial vaccine]. Binder P; du Colombier P; Bureau Fontanges R Poumon Coeur; 1982; 38(5):317-23. PubMed ID: 6760155 [TBL] [Abstract][Full Text] [Related]
40. Development and evaluation of a DNA vaccine based on Helicobacter pylori urease B: failure to prevent experimental infection in the mouse model. Zavala-Spinetti L; Breslin MB; Correa H; Bégué RE Helicobacter; 2006 Dec; 11(6):517-22. PubMed ID: 17083372 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]